Medivolve and Marvel Diagnostics Successfully Complete First Stage Clinical Testing of BlowFISH, a Non-Invasive Exhaled Breath Diagnostic Technology For COVID-19, Developed by a UCLA Research Team Led by Dr. Pirouz Kavehpour
Medivolve is well positioned to deliver shareholder value from its equity position in Marvel Diagnostics and the team’s successful development of BlowFISH, a non-invasive exhaled breath diagnostic technology that has cleared the first milestone in a series of clinical tests and has entered the next phase toward applying for an Emergency Use Authorization from the…